What question did this study set out to answer?

To evaluate whether IPSS-M downstaging before allogeneic transplantation improves patient outcomes in myelodysplastic syndromes.

IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds no survival benefit from IPSS-M downstaging in MDS patients before transplantation, suggesting alternate strategies.

To evaluate whether IPSS-M downstaging before allogeneic transplantation improves patient outcomes in myelodysplastic syndromes.
Retrospective analysis of 128 adults with myelodysplastic syndromes
Grouped patients as frontline transplantation (n = 87) or pretreated before transplant (n = 41)
Calculated IPSS-M at diagnosis and pre-transplant using cytogenetic and next-generation sequencing data
Frontline transplantation showed superior overall survival (median OS 112.6 vs 14.0 months)
Relapse-free survival was also better with frontline transplantation (median RFS 61.0 vs 8.9 months)
Non-relapse mortality was significantly higher after pretreatment (p = 0.018)

Richardson et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis finds no survival benefit from IPSS-M downstaging in MDS patients before transplantation, suggesting alternate strategies.